Insight Molecular Diagnostics I (IMDX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Insight Molecular Diagnostics I

NasdaqCM•Healthcare•Diagnostics & Research

$4.13+0.01(<0.01%)Market closed

Market Cap

$149.39M

P/S

89.5x

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

How this company scores

WeakMetricSide Score: 40/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability13/25

Growth8/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Interest easily coveredProfit converts from growthNet cash positionImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 89.5x5y range 12.7x – 1391.5x

Currently above its 17-quarter median.

P/B · 88.1x5y range 0.0x – 88.1x

Currently above its 15-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $149.39M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.67M
Q. Revenue: $239,000
TTM EBITDA: $-47.85M
TTM Op. Income: $-50.30M
Q. Op. Income: $-11.40M
TTM Net Income: $-49.36M
Q. Net Income: $-11.26M
EPS: $-0.31
Shares Out.: $36.75M

$1.67M in TTM revenue declined 60.8% YoY, reaching $239,000 last quarter. TTM EBITDA of $-47.85M and TTM operating income of $-50.30M show growth is flowing through to the bottom line. However, net income is negative at $49.36M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 65.7%
EBITDA Margin: -4492.5%
Op. Margin: -4770.7%
Net Margin: -4711.3%

Op. margin of -4770.7% is down 2870.7% YoY — costs are rising relative to revenue. Net margin at -4711.3% and gross margin of 65.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 151% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 89.5x
P/B Ratio: N/A

P/S of 89.5x and P/B of 0.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $29.44M
Cash: $17.76M
Long-Term Debt: N/A
Book Value: $-21.30M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-9.27M
TTM Free Cash Flow: $-30.88M
FCF Margin: -1848.8%
FCF / Net Income: 0.6

TTM FCF of $-30.88M on $-9.27M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.